IBS Trials Should Gauge Efficacy In Maintenance And Retreatment, FDA Says
Executive Summary
Agency’s final guidance on clinical evaluation of irritable bowel syndrome drugs says sponsors should assess benefits of maintenance therapy and repeated courses of treatment in addition to short-term efficacy. The recommendations on clinical endpoints are “provisional” pending development of new patient-reported outcome measures.
You may also be interested in...
Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015
With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.
FDA, Industry Seek Temporary Endpoint For Assessing Ulcerative Colitis Drugs
Panelists at an agency workshop discussed tweaks to the Mayo Clinic Score while patient-reported outcome instruments are being developed in an initiative to create an improved ulcerative colitis endpoint.
Schooled On Prilosec And Zelnorm: Ironwood/Forest Aim Linzess At OTC-Dominated Market
After FDA approval of Linzess, the commercial challenge of competing with over-the-counter laxatives begins. Ironwood is well-versed on the success story of proton pump inhibitors and the mixed record of withdrawn constipation/IBS drug Zelnorm when it comes to introducing a branded drug into the market.